Symbols / TEM Stock $46.95 -3.12% Tempus AI, Inc.

Healthcare • Health Information Services • United States • NMS
TEM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Health Information Services
CEO Mr. Eric P. Lefkofsky J.D.
Exch · Country NMS · United States
Market Cap 8.43B
Enterprise Value 9.11B
Income -302.91M
Sales 1.36B
FCF (ttm) -55.76M
Book/sh 2.76
Cash/sh 3.56
Employees 3,800
Insider 10d —
IPO Jun 14, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -345.65
PEG —
P/S 6.18
P/B 17.02
P/C —
EV/EBITDA -49.18
EV/Sales 6.68
Quick Ratio 2.99
Current Ratio 3.31
Debt/Eq 316.65
LT Debt/Eq —
EPS (ttm) -1.72
EPS next Y -0.14
EPS Growth —
Revenue Growth 36.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-05-05
ROA -9.07%
ROE -81.58%
ROIC —
Gross Margin 63.39%
Oper. Margin -24.33%
Profit Margin -22.20%
Shs Outstand 174.52M
Shs Float 113.56M
Insider Own 37.23%
Instit Own 56.74%
Short Float 27.03%
Short Ratio 5.05
Short Interest 26.76M
52W High 104.32
vs 52W High -54.99%
52W Low 41.73
vs 52W Low 12.51%
Beta —
Impl. Vol. 73.73%
Rel Volume 1.06
Avg Volume 5.65M
Volume 5.99M
Target (mean) $69.27
Tgt Median $68.00
Tgt Low $35.00
Tgt High $100.00
# Analysts 15
Recom Buy
Prev Close $48.46
Price $46.95
Change -3.12%
About

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$69.27
Mean price target
2. Current target
$46.95
Latest analyst target
3. DCF / Fair value
$-5.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$46.95
Low
$35.00
High
$100.00
Mean
$69.27

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 main HC Wainwright & Co. Buy → Buy $64
2026-05-08 main BTIG Buy → Buy $80
2026-05-06 main TD Cowen Buy → Buy $68
2026-04-13 init Jefferies — → Underperform $35
2026-03-30 main Guggenheim Buy → Buy $60
2026-03-11 reit Needham Buy → Buy $75
2026-03-09 main HC Wainwright & Co. Buy → Buy $95
2026-03-03 main Morgan Stanley Overweight → Overweight $70
2026-02-25 main JP Morgan Neutral → Neutral $60
2026-02-25 main Needham Buy → Buy $75
2026-02-25 main BTIG Buy → Buy $90
2026-02-19 init Mizuho — → Outperform $100
2026-02-17 init Baird — → Outperform $59
2025-12-22 main Canaccord Genuity Buy → Buy $80
2025-12-15 main JP Morgan Neutral → Neutral $80
2025-12-02 main Morgan Stanley Overweight → Overweight $85
2025-11-25 main BTIG Buy → Buy $105
2025-11-11 main Piper Sandler Neutral → Neutral $80
2025-11-11 main Morgan Stanley Overweight → Overweight $80
2025-11-07 main HC Wainwright & Co. Buy → Buy $89
News
RSS: Latest TEM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-04 POLOVIN ANDREW Officer — 10,000 $0.00 $0
2026-05-04 SCHOENHERR THOMAS EDWARD Officer — 13,642 $0.00 $0
2026-05-04 BARTOLUCCI RYAN M Officer — 24,000 $0.00 $0
2026-05-04 FUKUSHIMA RYAN Officer — 10,000 $0.00 $0
2026-05-04 ROGERS JAMES WILLIAM Chief Financial Officer — 10,000 $0.00 $0
2026-04-28 LEFKOFSKY ERIC PAUL Chief Executive Officer — 166,250 $51.03 $8,500,623
2026-03-26 LEFKOFSKY ERIC PAUL Chief Executive Officer — 166,250 $45.78 $7,711,150
2026-03-02 ROGERS JAMES WILLIAM Chief Financial Officer — 11,414 $50.69 $578,576
2026-03-02 EPSTEIN DAVID R Director — 250 $50.69 $12,672
2026-02-20 POLOVIN ANDREW Officer — 19,092 $59.05 $1,141,136
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,271.79
+83.41%
693.40
+30.38%
531.82
+65.85%
320.67
Operating Revenue
1,271.79
+83.41%
693.40
+30.38%
531.82
+65.85%
320.67
Cost Of Revenue
473.89
+51.75%
312.29
+27.13%
245.65
+28.96%
190.48
Reconciled Cost Of Revenue
387.88
+35.03%
287.26
+30.20%
220.63
+15.83%
190.48
Gross Profit
797.90
+109.36%
381.11
+33.17%
286.18
+119.82%
130.19
Operating Expense
1,050.77
-2.00%
1,072.19
+122.33%
482.26
+21.90%
395.63
Research And Development
319.03
+0.69%
316.84
+70.81%
185.50
+14.33%
162.25
Selling General And Administration
715.43
-3.73%
743.13
+157.64%
288.44
+23.59%
233.38
Total Expenses
1,524.66
+10.13%
1,384.48
+90.20%
727.90
+24.19%
586.11
Operating Income
-252.87
+63.41%
-691.08
-252.44%
-196.08
+26.13%
-265.44
Total Operating Income As Reported
-252.87
+63.41%
-691.08
-252.44%
-196.08
+26.13%
-265.44
EBITDA
-118.51
+80.59%
-610.42
-357.83%
-133.33
+43.71%
-236.85
Normalized EBITDA
-106.47
+82.56%
-610.42
-357.83%
-133.33
+43.71%
-236.85
Reconciled Depreciation
102.32
+174.73%
37.24
+11.74%
33.33
+9.61%
30.41
EBIT
-220.83
+65.90%
-647.66
-288.61%
-166.66
+37.64%
-267.26
Total Unusual Items
-12.03
0.00
0.00
—
Total Unusual Items Excluding Goodwill
-12.03
0.00
0.00
—
Special Income Charges
-12.03
0.00
0.00
—
Other Special Charges
12.03
—
—
—
Net Income
-245.03
+65.28%
-705.81
-229.64%
-214.12
+26.12%
-289.81
Pretax Income
-291.10
+58.49%
-701.32
-228.44%
-213.53
+26.15%
-289.15
Net Non Operating Interest Income Expense
-57.64
-35.40%
-42.57
-8.41%
-39.27
-108.19%
-18.86
Interest Expense Non Operating
70.27
+30.97%
53.65
+14.47%
46.87
+114.07%
21.89
Net Interest Income
-57.64
-35.40%
-42.57
-8.41%
-39.27
-108.19%
-18.86
Interest Expense
70.27
+30.97%
53.65
+14.47%
46.87
+114.07%
21.89
Interest Income Non Operating
12.63
+13.93%
11.08
+45.82%
7.60
+150.69%
3.03
Interest Income
12.63
+13.93%
11.08
+45.82%
7.60
+150.69%
3.03
Other Income Expense
19.41
-39.96%
32.34
+48.18%
21.82
+550.31%
-4.85
Other Non Operating Income Expenses
31.45
-2.75%
32.34
+48.18%
21.82
+550.31%
-4.85
Tax Provision
-51.68
-19530.08%
0.27
-7.64%
0.29
+336.36%
0.07
Tax Rate For Calcs
0.00
-15.43%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-2.14
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-245.03
+65.28%
-705.81
-229.64%
-214.12
+26.12%
-289.81
Net Income From Continuing Operation Net Minority Interest
-245.03
+65.28%
-705.81
-229.64%
-214.12
+26.12%
-289.81
Net Income From Continuing And Discontinued Operation
-245.03
+65.28%
-705.81
-229.64%
-214.12
+26.12%
-289.81
Net Income Continuous Operations
-245.03
+65.28%
-705.81
-229.64%
-214.12
+26.12%
-289.81
Normalized Income
-235.13
+66.69%
-705.81
-229.64%
-214.12
+26.12%
-289.81
Net Income Common Stockholders
-245.03
+67.17%
-746.33
-180.61%
-265.96
+20.35%
-333.93
Otherunder Preferred Stock Dividend
0.00
0.00
-100.00%
4.34
+1341.20%
0.30
Diluted EPS
-1.41
+77.37%
-6.23
-286.11%
-1.61
+69.35%
-5.26
Basic EPS
-1.41
+77.37%
-6.23
-286.11%
-1.61
+69.35%
-5.26
Basic Average Shares
174.26
+45.40%
119.85
-27.29%
164.83
+159.87%
63.43
Diluted Average Shares
174.26
+45.40%
119.85
-27.29%
164.83
+159.87%
63.43
Diluted NI Availto Com Stockholders
-245.03
+67.17%
-746.33
-180.61%
-265.96
+20.35%
-333.93
Depreciation Amortization Depletion Income Statement
16.31
+33.47%
12.22
+46.89%
8.32
—
Depreciation And Amortization In Income Statement
16.31
+33.47%
12.22
+46.89%
8.32
—
Depreciation Income Statement
16.31
+33.47%
12.22
+46.89%
8.32
—
Earnings From Equity Interest Net Of Tax
-5.61
-32.78%
-4.23
-1304.65%
-0.30
+49.41%
-0.59
Preferred Stock Dividends
—
40.52
-14.71%
47.51
+8.43%
43.82
Line Item Trend 2025-12-31 2024-12-31
Total Assets
2,274.84
+145.63%
926.12
Current Assets
1,167.17
+74.83%
667.60
Cash Cash Equivalents And Short Term Investments
755.00
+68.43%
448.26
Cash And Cash Equivalents
604.79
+77.38%
340.95
Other Short Term Investments
150.21
+39.98%
107.31
Receivables
319.95
+106.66%
154.82
Accounts Receivable
311.17
+100.99%
154.82
Gross Accounts Receivable
313.93
+101.29%
155.96
Allowance For Doubtful Accounts Receivable
-2.75
-141.45%
-1.14
Inventory
51.72
+34.75%
38.39
Current Deferred Assets
—
0.00
Hedging Assets Current
—
0.00
Other Current Assets
40.50
+54.96%
26.14
Total Non Current Assets
1,107.66
+328.47%
258.51
Net PPE
153.65
+111.01%
72.82
Gross PPE
291.00
+63.28%
178.22
Accumulated Depreciation
-137.35
-30.31%
-105.40
Properties
0.00
0.00
Land And Improvements
9.85
0.00
Buildings And Improvements
1.23
0.00
Machinery Furniture Equipment
6.98
+5.17%
6.63
Other Properties
208.15
+66.82%
124.77
Leases
64.79
+38.42%
46.81
Goodwill And Other Intangible Assets
825.46
+870.46%
85.06
Goodwill
470.21
+541.11%
73.34
Other Intangible Assets
355.25
+2932.20%
11.72
Investments And Advances
86.56
-5.35%
91.45
Long Term Equity Investment
86.56
-5.35%
91.45
Non Current Accounts Receivable
16.21
—
Other Non Current Assets
25.77
+180.59%
9.19
Total Liabilities Net Minority Interest
1,783.51
+105.05%
869.78
Current Liabilities
372.39
+27.94%
291.07
Payables And Accrued Expenses
203.94
+26.72%
160.94
Payables
82.33
+5.23%
78.24
Accounts Payable
81.99
+52.39%
53.80
Dividends Payable
—
0.00
Current Accrued Expenses
121.61
+47.05%
82.70
Pensionand Other Post Retirement Benefit Plans Current
37.78
+52.54%
24.77
Total Tax Payable
0.34
-98.61%
24.44
Current Debt And Capital Lease Obligation
13.36
+106.77%
6.46
Current Capital Lease Obligation
13.36
+106.77%
6.46
Current Deferred Liabilities
108.63
+18.16%
91.94
Current Deferred Revenue
108.63
+18.16%
91.94
Other Current Liabilities
8.68
+24.64%
6.96
Total Non Current Liabilities Net Minority Interest
1,411.12
+143.84%
578.71
Long Term Debt And Capital Lease Obligation
1,313.78
+184.59%
461.63
Long Term Debt
1,239.50
+184.66%
435.44
Long Term Capital Lease Obligation
74.27
+183.49%
26.20
Tradeand Other Payables Non Current
12.39
-82.41%
70.45
Non Current Deferred Liabilities
28.36
-7.46%
30.64
Non Current Deferred Revenue
28.36
-7.46%
30.64
Other Non Current Liabilities
56.60
+254.19%
15.98
Preferred Securities Outside Stock Equity
0.00
0.00
Stockholders Equity
491.33
+772.09%
56.34
Common Stock Equity
491.33
+772.09%
56.34
Capital Stock
0.02
+5.88%
0.02
Common Stock
0.02
+5.88%
0.02
Share Issued
178.46
+10.08%
162.12
Ordinary Shares Number
178.28
+10.07%
161.98
Treasury Shares Number
0.18
+25.96%
0.15
Additional Paid In Capital
2,892.91
+30.86%
2,210.66
Retained Earnings
-2,395.86
-11.39%
-2,150.83
Gains Losses Not Affecting Retained Earnings
0.90
+859.57%
0.09
Treasury Stock
6.64
+84.40%
3.60
Other Equity Adjustments
0.90
+859.57%
0.09
Total Equity Gross Minority Interest
491.33
+772.09%
56.34
Total Capitalization
1,730.83
+251.96%
491.77
Working Capital
794.79
+111.08%
376.53
Invested Capital
1,730.83
+251.96%
491.77
Total Debt
1,327.13
+183.52%
468.09
Net Debt
634.72
+571.79%
94.48
Capital Lease Obligations
87.63
+168.32%
32.66
Net Tangible Assets
-334.14
-1063.43%
-28.72
Tangible Book Value
-334.14
-1063.43%
-28.72
Derivative Product Liabilities
—
0.00
Duefrom Related Parties Current
8.79
0.00
Duefrom Related Parties Non Current
16.21
0.00
Financial Assets
—
0.00
Interest Payable
2.83
-67.34%
8.66
Investmentsin Joint Venturesat Cost
86.56
-5.35%
91.45
Non Current Accrued Expenses
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-218.09
-15.36%
-189.04
+11.80%
-214.34
-27.43%
-168.20
Cash Flow From Continuing Operating Activities
-218.09
-15.36%
-189.04
+11.80%
-214.34
-27.43%
-168.20
Net Income From Continuing Operations
-245.03
+65.28%
-705.81
-229.64%
-214.12
+26.12%
-289.81
Depreciation Amortization Depletion
102.32
+174.73%
37.24
+11.74%
33.33
+9.61%
30.41
Depreciation
102.32
+174.73%
37.24
+11.74%
33.33
+9.61%
30.41
Depreciation And Amortization
102.32
+174.73%
37.24
+11.74%
33.33
+9.61%
30.41
Other Non Cash Items
25.59
+17.07%
21.86
+29.48%
16.89
+103.97%
8.28
Stock Based Compensation
124.75
-76.65%
534.14
0.00
0.00
Provisionand Write Offof Assets
3.89
+472.50%
0.68
-58.69%
1.65
-71.65%
5.80
Asset Impairment Charge
0.00
0.00
-100.00%
7.36
0.00
Deferred Tax
-52.66
0.00
0.00
—
Deferred Income Tax
-52.66
0.00
0.00
—
Operating Gains Losses
1.59
+104.04%
-39.36
-82.16%
-21.61
-508.05%
5.29
Gain Loss On Investment Securities
-16.47
+62.21%
-43.59
-98.96%
-21.91
-566.11%
4.70
Gain Loss On Sale Of PPE
0.41
0.00
0.00
—
Change In Working Capital
-178.55
-372.31%
-37.80
+0.09%
-37.84
-152.68%
71.82
Change In Receivables
-90.40
-48.11%
-61.04
-730.77%
-7.35
+10.44%
-8.20
Changes In Account Receivables
-90.40
-48.11%
-61.04
-730.77%
-7.35
+10.44%
-8.20
Change In Inventory
-3.37
+64.69%
-9.54
-45.38%
-6.56
-400.23%
-1.31
Change In Prepaid Assets
-1.70
+87.58%
-13.68
-111.35%
-6.47
-491.77%
-1.09
Change In Payables And Accrued Expense
-2.91
-107.91%
36.82
+67.89%
21.93
-10.63%
24.54
Change In Accrued Expense
4.33
-92.87%
60.67
+33.95%
45.29
+39.57%
32.45
Change In Payable
-7.24
+69.64%
-23.85
-2.09%
-23.36
-195.17%
-7.92
Change In Account Payable
-7.24
+69.64%
-23.85
-2.09%
-23.36
-195.17%
-7.92
Change In Other Working Capital
-22.91
-220.96%
18.95
+171.73%
-26.41
-139.06%
67.63
Change In Other Current Assets
-42.30
-5532.62%
-0.75
+82.16%
-4.21
-83.32%
-2.30
Change In Other Current Liabilities
-14.95
-74.77%
-8.55
+2.37%
-8.76
-17.77%
-7.44
Investing Cash Flow
-398.36
-205.51%
-130.39
-223.45%
-40.31
+30.42%
-57.94
Cash Flow From Continuing Investing Activities
-398.36
-205.51%
-130.39
-223.45%
-40.31
+30.42%
-57.94
Net PPE Purchase And Sale
-21.05
+4.85%
-22.12
+36.08%
-34.61
-88.32%
-18.38
Purchase Of PPE
-21.05
+4.85%
-22.12
+36.08%
-34.61
-88.32%
-18.38
Capital Expenditure
-27.27
-23.25%
-22.12
+36.08%
-34.61
-88.32%
-18.38
Capital Expenditure Reported
-6.22
0.00
0.00
—
Net Investment Purchase And Sale
5.58
+142.61%
-13.09
0.00
0.00
Purchase Of Investment
-2.74
+92.43%
-36.18
0.00
0.00
Sale Of Investment
8.32
-64.00%
23.10
0.00
0.00
Net Business Purchase And Sale
-376.67
-295.72%
-95.19
-1568.47%
-5.71
+85.58%
-39.56
Purchase Of Business
-376.67
-295.72%
-95.19
-1568.47%
-5.71
+85.58%
-39.56
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
884.12
+78.85%
494.33
+320.54%
117.55
-53.24%
251.39
Cash Flow From Continuing Financing Activities
884.12
+78.85%
494.33
+320.54%
117.55
-53.24%
251.39
Net Issuance Payments Of Debt
735.76
0.00
-100.00%
82.59
-51.49%
170.25
Issuance Of Debt
1,020.50
0.00
-100.00%
82.88
-51.43%
170.62
Repayment Of Debt
-284.73
0.00
+100.00%
-0.29
+23.20%
-0.38
Long Term Debt Issuance
1,020.50
0.00
-100.00%
82.88
-51.43%
170.62
Long Term Debt Payments
-284.73
0.00
+100.00%
-0.29
+23.20%
-0.38
Net Long Term Debt Issuance
735.76
0.00
-100.00%
82.59
-51.49%
170.25
Net Common Stock Issuance
192.46
-49.61%
381.95
+10703.86%
-3.60
0.00
Common Stock Payments
-3.04
0.00
+100.00%
-3.60
0.00
Cash Dividends Paid
0.00
+100.00%
-5.62
+0.00%
-5.62
+0.00%
-5.62
Repurchase Of Capital Stock
-3.04
-35.11%
-2.25
+37.53%
-3.60
0.00
Net Other Financing Charges
-44.10
+44.53%
-79.50
-11289.26%
-0.70
+87.15%
-5.43
Changes In Cash
267.68
+53.05%
174.89
+227.56%
-137.10
-643.03%
25.25
Effect Of Exchange Rate Changes
-0.06
-118.45%
0.34
+1868.42%
-0.02
-211.76%
0.02
Beginning Cash Position
341.83
+105.17%
166.61
-45.15%
303.73
+9.07%
278.47
End Cash Position
609.45
+78.29%
341.83
+105.17%
166.61
-45.15%
303.73
Free Cash Flow
-245.35
-16.19%
-211.17
+15.18%
-248.95
-33.43%
-186.58
Interest Paid Supplemental Data
—
28.05
+65.82%
16.91
+262.63%
4.66
Income Tax Paid Supplemental Data
—
0.21
+27.95%
0.16
+2583.33%
0.01
Change In Interest Payable
14.21
-6.10%
15.13
-4.46%
15.84
-3.41%
16.39
Common Stock Issuance
195.50
-48.82%
381.95
0.00
0.00
Earnings Losses From Equity Investments
5.61
+32.78%
4.23
+1304.65%
0.30
-49.41%
0.59
Issuance Of Capital Stock
195.50
-66.39%
581.70
+1195.98%
44.88
-51.32%
92.20
Net Preferred Stock Issuance
0.00
-100.00%
197.50
+340.01%
44.88
-51.32%
92.20
Preferred Stock Issuance
0.00
-100.00%
199.75
+345.03%
44.88
-51.32%
92.20
Preferred Stock Payments
0.00
+100.00%
-2.25
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category